Literature DB >> 10575040

Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation.

L A Lione1, R J Carter, M J Hunt, G P Bates, A J Morton, S B Dunnett.   

Abstract

Cognitive decline is apparent in the early stages of Huntington's disease and progressively worsens throughout the course of the disease. Expression of the human Huntington's disease mutation in mice (R6/2 line) causes a progressive neurological phenotype with motor symptoms resembling those seen in Huntington's disease. Here we describe the cognitive performance of R6/2 mice using four different tests (Morris water maze, visual cliff avoidance, two-choice swim tank, and T-maze). Behavioral testing was performed on R6/2 transgenic mice and their wild-type littermates between 3 and 14.5 weeks of age, using separate groups of mice for each test. R6/2 mice did not show an overt motor phenotype until approximately 8 weeks of age. However, between 3.5 and 8 weeks of age, R6/2 mice displayed progressive deterioration in specific aspects of learning in the Morris water maze, visual cliff, two-choice swim tank, and T-maze tasks. The age of onset and progression of the deficits in the individual tasks differed depending on the particular task demands. Thus, as seen in humans with Huntington's disease, R6/2 mice develop progressive learning impairments on cognitive tasks sensitive to frontostriatal and hippocampal function. We suggest that R6/2 mice provide not only a model for studying cognitive and motor changes in trinucleotide repeat disorders, but also a framework within which the functional efficacy of therapeutic strategies aimed at treating such diseases can be tested.

Entities:  

Mesh:

Year:  1999        PMID: 10575040      PMCID: PMC6782405     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  43 in total

1.  Spontaneous alternation behavior.

Authors:  W N DEMBER; H FOWLER
Journal:  Psychol Bull       Date:  1958-11       Impact factor: 17.737

2.  Striking changes in anxiety in Huntington's disease transgenic mice.

Authors:  S E File; A Mahal; L Mangiarini; G P Bates
Journal:  Brain Res       Date:  1998-09-14       Impact factor: 3.252

Review 3.  Synaptic plasticity.

Authors:  C F Stevens; J Sullivan
Journal:  Curr Biol       Date:  1998-02-26       Impact factor: 10.834

4.  Hippocampal lesions cause learning deficits in inbred mice in the Morris water maze and conditioned-fear task.

Authors:  S F Logue; R Paylor; J M Wehner
Journal:  Behav Neurosci       Date:  1997-02       Impact factor: 1.912

5.  Age dependence of striatal neuronal death caused by mitochondrial dysfunction.

Authors:  S R Bossi; J R Simpson; O Isacson
Journal:  Neuroreport       Date:  1993-01       Impact factor: 1.837

6.  Executive and mnemonic functions in early Huntington's disease.

Authors:  A D Lawrence; B J Sahakian; J R Hodges; A E Rosser; K W Lange; T W Robbins
Journal:  Brain       Date:  1996-10       Impact factor: 13.501

7.  Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid.

Authors:  E Brouillet; B G Jenkins; B T Hyman; R J Ferrante; N W Kowall; R Srivastava; D S Roy; B R Rosen; M F Beal
Journal:  J Neurochem       Date:  1993-01       Impact factor: 5.372

8.  Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease.

Authors:  C V Borlongan; T K Koutouzis; T B Freeman; D W Cahill; P R Sanberg
Journal:  Brain Res       Date:  1995-10-30       Impact factor: 3.252

9.  Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin.

Authors:  G Schilling; M W Becher; A H Sharp; H A Jinnah; K Duan; J A Kotzuk; H H Slunt; T Ratovitski; J K Cooper; N A Jenkins; N G Copeland; D L Price; C A Ross; D R Borchelt
Journal:  Hum Mol Genet       Date:  1999-03       Impact factor: 6.150

10.  Deficits in memory and hippocampal long-term potentiation in mice with reduced calbindin D28K expression.

Authors:  S Molinari; R Battini; S Ferrari; L Pozzi; A S Killcross; T W Robbins; A Jouvenceau; J M Billard; P Dutar; Y Lamour; W A Baker; H Cox; P C Emson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

View more
  93 in total

Review 1.  Modeling human neurodegenerative diseases in transgenic systems.

Authors:  Miguel A Gama Sosa; Rita De Gasperi; Gregory A Elder
Journal:  Hum Genet       Date:  2011-12-14       Impact factor: 4.132

2.  Reduced expression of conditioned fear in the R6/2 mouse model of Huntington's disease is related to abnormal activity in prelimbic cortex.

Authors:  Adam G Walker; Jason R Ummel; George V Rebec
Journal:  Neurobiol Dis       Date:  2011-04-16       Impact factor: 5.996

Review 3.  Neural transplantation in patients with Huntington's disease.

Authors:  Anne E Rosser; Stephen B Dunnett
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 4.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

Review 5.  Dopamine Receptors and Neurodegeneration.

Authors:  Claudia Rangel-Barajas; Israel Coronel; Benjamín Florán
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

6.  Neuroprotective and neurorestorative strategies for neuronal injury.

Authors:  M F Beal; T Palomo; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

7.  Dysregulated information processing by medium spiny neurons in striatum of freely behaving mouse models of Huntington's disease.

Authors:  Benjamin R Miller; Adam G Walker; Anand S Shah; Scott J Barton; George V Rebec
Journal:  J Neurophysiol       Date:  2008-07-30       Impact factor: 2.714

8.  Longitudinal Biochemical Assay Analysis of Mutant Huntingtin Exon 1 Protein in R6/2 Mice.

Authors:  Eva L Morozko; Joseph Ochaba; Sarah J Hernandez; Alice Lau; Isabella Sanchez; Iliana Orellana; Lexi Kopan; Joshua Crapser; Janet H Duong; Julia Overman; Silvia Yeung; Joan S Steffan; Jack Reidling; Leslie M Thompson
Journal:  J Huntingtons Dis       Date:  2018

9.  Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington's disease.

Authors:  Birgit Zucker; Dagmar E Ludin; Thomas A Gerds; Carl H Lücking; G Bernhard Landwehrmeyer; Thomas J Feuerstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-30       Impact factor: 3.000

10.  Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease.

Authors:  Carlos Cepeda; Raymond S Hurst; Christopher R Calvert; Elizabeth Hernández-Echeagaray; Oanh K Nguyen; Emily Jocoy; Lindsey J Christian; Marjorie A Ariano; Michael S Levine
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.